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OBJECTIVE: To determine age-related variations in prostate
cancer (PC) patients’ utilities. PC is a disease of older men. Deci-
sions regarding its management are sensitive to preferences for
outcomes. METHODS: We derived a population-based sample
of PC patients diagnosed in 1992, 1997 or 2002 from the
Ontario Cancer Registry. Patients (n = 1531). Consenting sur-
vivors were mailed questionnaires, includingdemographics,
Health Utilities Index (HUI2/3), and UCLA Prostate Cancer
Index (PCI). We computed Pearson’s correlations between HUI3
utility and PCI scores in all patients and between age quartiles.
We used regression to test for interactions, namely linear trends
in HUI3-PCI slopes across age quartiles. RESULTS: The ﬁrst 289
patients returned questionnaires in 2004. Mean age was 71.6
years. Primary treatments, received 1–11 years prior, were
prostatectomy (46%), radiation (32%), hormones only (12%),
and watchful waiting (10%). Mean HUI3 utility was 0.79, SD
= 0.24. HUI3 and sexual function scores decreased with age (p
< 0.001), but urinary function improved (p = 0.01), with no
changes in bother scores. For HUI3 and sexual function, r = 0.43
(p < 0.001) for 44–65yr olds, and r = 0.14 (p = 0.28.) for 78–
92yr olds, p = 0.35 for interaction. For HUI3 and sexual bother,
r = 0.41 for 44–65yr olds, and r = 0.09 for 78–92yr olds, p =
0.06 for interaction. Correlations between HUI3 and urinary
function increased with age (from 0.24 to 0.43, p = 0.04 for
interaction). Similar age effects were observed for urinary bother.
There were no age-related trends for correlations between HUI3
and bowel function or bother. Sexual and urinary function scores
became less strongly related to their corresponding bother scores
as age increased (p < 0.002). CONCLUSIONS: Although sexual
dysfunction increased with age, it became less bothersome and
had less impact on utility. However, older patients’ quality of life
was more affected by urinary dysfunction. Modelers and policy-
makers may need to adjust utilities for PC health states for
patient age.
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ONLINE REPORTING OF TOXICITY SYMPTOMS BY LUNG
CANCER PATIENTS DURING CHEMOTHERAPY
Basch E, Barz A, Kris M, Culkin A, Schrag D
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OBJECTIVES: To determine whether lung cancer patients can
be engaged to report their own toxicity-related symptoms during
chemotherapy. METHODS: The NCI’s Common Terminology
Criteria for Adverse Events (CTCAE) schema for nine common
symptoms was adapted into a web-based patient-reporting
system, accessible from computers in outpatient clinics and from
home computers. Outpatients with lung malignancies beginning
standard chemotherapy regimens were invited to enroll. During
a 16-week observation period, participants were encouraged to
login and report symptoms at each follow-up visit, or alterna-
tively to access the system from home. Severe toxicities entered
into the system (grade 3–4) triggered emails to the primary clin-
ical team. RESULTS: A total of 108 patients were approached,
with 23 refusals due to anxiety (n = 4), unwillingness to use a
computer (n = 5), or no perceived beneﬁt (n = 6). All 93 enrollees
completed an initial login. At each subsequent appointment,
most enrollees (80–85%) reported symptoms using the online
system, with a mean of 7 visits per patient (range 1–16). A total
of 79/93 (85%) logged in at more than two-thirds of appoint-
ments. Only 12/93 (13%) voluntarily logged in at least once
from home, with a mean of 10 logins among home users versus
6 among non-home users. Utilization was signiﬁcantly associated
with prior Internet experience but not with age, cancer type,
ECOG score, income, or education level. A total of 121 severe
toxicities were entered into the system, including 17 from home
users, which were delivered via email to treating clinicians for
consideration of interventions. CONCLUSION: Lung cancer
patients are capable of reporting symptoms experienced during
chemotherapy via the web, but may be less willing than other
populations to use computers, and less apt to self-report from
home. Assessment in other populations, in a clinical trial setting,
and comparison of patient versus clinician symptom reporting
are being performed in separate studies.
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OBJECTIVE: Anti-Coagulant therapy is often prescribed for
patients in the hospitals who are at high risk for a deep vein
thrombosis or pulmonary embolism (DVT/PE). The purpose of
this study is to determine if there are better outcomes for patients
who start anti-coagulant therapy on day one as opposed to later
in their stay. METHODS: A retrospective study was conducted
with 391,253 patients who had Lovenox discharged between
January 2001 through June 2005 extracted from Solucient’s
ACTracker Database and grouped into a cohort of 206,456
patients who received the drug on day one and a group of
184,797 patients who received the drug afterwards as the com-
parison group. Economic and clinical outcomes were measured
with the following metrics by different risk adjust methods 1).
length of stay (LOS), ICU LOS, and total costs within risk
adjusted RDRGs, as well as 2). the results of Risk-Adjusted Mor-
tality (RAMI) and Complication (ECRI) indices. RESULTS: In
comparing those patients who received an anti-coagulant on the
ﬁrst day versus anytime after, we found that day one treated
patients had signiﬁcantly shorter weighted average and ICU
weighted average LOS with a difference of 0.87 days (p <
0.0001) and 0.40 days (p < 0.0001) on average respectively. A
signiﬁcantly decreased weighted average total cost in patients
receiving the drug earlier was also observed with a difference of
$806 (p < 0.0001). In clinical perspectives, earlier treated
Lovenox patients were found to have both lower mortality index
(0.96 vs. 1.04, p < 0.0001) and lower complication rates (0.94
vs. 1.05, p < 0.01). CONCLUSION: Patients who received pro-
phylaxis anti-coagulant therapy on their ﬁrst day of an inpatient
stay have better economic and clinical outcomes than those who
receive anti-coagulants later in their stay.
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RETROSPECTIVE STUDY OF PATIENTS WITH CABG
REOPERATION AND OUTCOMES
He J, Grifﬁn B,Wang C
Solucient, Berkerley Heights, NJ, USA
OBJECTIVES: Mortality and morbidity of patients with Coro-
nary Artery Bypass Grafting (CABG) reoperation (redo) are
reportedly signiﬁcantly higher than those of ﬁrst-time CABG
population. Performing initial CABG properly and preventing
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CABG redo increasingly become more and more important both
clinically and economically. METHODS: A retrospective study
was conducted among a population of 256,806 patients with
initial CABG performed during the time period of January 2001
to February 2005. Data were collected from 332 hospitals out
of the Solucient® ACTrackerTM inpatient database. Multivariate
logistic regression was used to identify factors contributed to
CABG performance and propensity score adjustment was
applied. Patient demographic, hospital characteristics (hospital
bed size, region, teaching and PCI annual volume), disease con-
dition (Chronic Obstructive Pulmonary Disease, COPD; Periph-
eral Vascular disease, PVD; Diabetes Mellitus, DM and
Malignancy, MA), related therapeutic drugs class (Anticoagu-
lant, Antiplatelet, GP2b3a, Asprin and Statins) usages during
hospital stay, patient severity and risk adjust mortality index and
on and off pump were introduced to logistic regression analysis.
RESULTS: The patient demographics, hospital characteristics
and disease conditions were controlled for comparison between
CABG and CABG redo population (P > 0.05) except that male
tended to have more CABG redo (OR: 1.2977, CI:
1.0956–1.5371). A total of 581 (0.22%) patients were found to
have undergone CABG redo in an average of 350 days. Con-
comitant drug uses were studied. Anitcoagulant (OR: 3.649, CI:
3.353–3.971) and GP2b3a (OR: 1.480, CI: 1.331–1.647) have
been found to not help with outcomes of the CABG patient while
Asprin (OR: 0.308, CI: 0.28–0.335) and Statin (OR: 0.544, CI:
0.506–0.585) were found to signiﬁcantly impact the outcomes
of CABG performance. CONCLUSIONS: The study conﬁrmed
that patients with CABG redo had worse outcomes than those
with one CABG (5.34% vs. 3.03%, p < 0.01). Detail drug usage
studies are recommended to ﬁnd out how to prevent patients
from CABG redo in the initial treatment.
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THE IMPACT OF MYOCARDIAL PERFUSION IMAGING FOR
DETECTION OF CORONARY ARTERY DISEASE ON THE
HEALTH OUTCOMES OF ASYMPTOMATIC PATIENTS WITH
TYPE 2 DIABETES
Marangos PJ1, Papatheofanis FJ2
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OBJECTIVE: The objective of this investigation is to determine
whether the results of myocardial perfusion imaging (MPI) for
detection of coronary artery disease (CAD) results in improved
new health outcomes in asymptomatic patients with Type-2 dia-
betes. The potential value of MPI is highlighted by the demon-
strated association between patients with diabetes mellitus and
the accelerated development of CAD, the fact that myocardial
ischemia due to coronary atherosclerosis is commonly asympto-
matic and the proven improvement in health outcomes in
patients treated with coronary artery bypass grafting (CABG).
METHODS: A retrospective observational study was conducted
using data from a Veterans’ Health System database, which
included detailed diagnosis codes and three-year clinical follow-
up of out-patient and in-patient encounters. We examined
whether the presence of coded diagnoses for angina in patients
also diagnosed with diabetes was associated with increased coro-
nary artery abnormalities detected by MPI; we also examined the
rates of cardiac intervention and subsequent cardiac events. A
total of 517 patients who underwent MPI during the observa-
tion interval were included in the analysis; 520 matched patients
who did not undergo MPI were used for comparison. RESULTS:
Over 31.9% of MPI studies were abnormal and indicated
ischemic or ﬁxed perfusion defects, or both. Forty-one patients
in the MPI cohort experienced cardiac death and 66 suffered MI,
whereas in the comparator cohort 68 (OR 2.4 [95% CI
1.4–6.2]); p < 0.01) suffered cardiac death and 97 suffered MI
(OR 4.4 [95% CI 2.6–9.6]; p < 0.01). The rate of CABG was
approximately four-fold greater in the MPI cohort and the rate
of both PTCA and CABG was three-fold greater in the MPI
cohort. CONCLUSION: Findings from this retrospective analy-
sis of MPI in asymptomatic patients with CAD and Type-2 dia-
betes has demonstrated that MPI resulted in interventions that
reduced hard and soft cardiac events.
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A NATIONAL STUDY PREDICTING THE INFLUENCE OF
PAYMENT SOURCES ON THE THIAZIDE DIURETICS
UTILIZATION FOR HYPERTENSION
Rahman A
Shenandoah University, Winchester,VA, USA
OBJECTIVES: It costs $12 billion annually for the management
of hypertension in U.S. Drug therapy is a major cost associated
with the management of hypertension. The Seventh Report of
the Joint National Committee on Prevention, Detection, Evalu-
ation, and Treatment of High Blood Pressure (JNC-7) issued new
guidelines for hypertension management. One of their guidelines
is that thiazide-type diuretics should be used in the therapy of
most patients with hypertension either alone in combination
with other drugs. Diuretics enhance the efﬁcacy of the multidrug
regimens and are more affordable than other antihypertensive
agents. Despite these recommendations, thiazide diuretics remain
underused. Literature review indicates that patient’ payment
sources might inﬂuence the drug utilization for hypertension.
This study examines the inﬂuence of various patients payment
source on the thiazide diuretics utilization for hypertension in
hospital ambulatory setting. METHODS: Patient payment
sources such as Self Pay, Medicare, Medicaid, HMO’s, and PPO’s
were used as independent variables to determine their inﬂuence
on the thiazide diuretics utilization for hypertensive patients.
Data from the National Hospital Ambulatory Medical Care
Survey (NHAMCS) 2003 were utilized. Patients with principal
diagnosis of Hypertension (ICD-9 code 401–404) were analyzed
using ANOVA, multiple linear and binomial logit regression
models. RESULTS: Hypertensive Patients with Federal source of
payments (Medicaid and Medicare) were prescribed signiﬁcantly
lower number of thiazide diuretics compared to patients with
other sources of payments (R2 = 0.116). Patients with (HMO’s
+ PPO’s) and self-pay as their primary source of payments 
were prescribed signiﬁcantly higher number of thiazide diuretics
compared to patients with other source of payments (R2 = 0.364)
and (R2 = 0.287) respectively. CONCLUSIONS: Thiazide diuret-
ics utilization for hypertensive patients are signiﬁcantly 
inﬂuenced by patients’ source of payments. Patients with
HMO’s, PPO’s and self-pay as their source of payment 
appears to appropriately adhere to the (JNC-7) guidelines for
hypertension.
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OBJECTIVES: Underused and inadequate care can adversely
affect patient health. Missed opportunities often occur in
primary care because process ﬂow models are not optimized to
make effective use of established clinical knowledge. To bridge
the gap between knowledge and practice we tested an electronic
